Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

NCT07466303 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Interventions

DRUG: Serplulimab
DRUG: SHR-A1811

Sponsor

Xijing Hospital